|
|
To achieve diverse patient participation, stakeholders must adapt protocols to include varied races, ethnicities, ages, sexual orientations, and gender identities. Discover how listening to patients and following FDA guidance can enhance clinical trials. |
|
|
|
Despite global clinical trial growth for hepatocellular carcinoma, India's participation remains low. Explore India's potential for HCC trials in this white paper, covering epidemiology, perceptions, and international research opportunities. |
|
|
|
Ready to break into the U.S. biopharma market? For APAC companies, it is important to identify the differences in standards of care, formulate robust strategies for compliance, and develop smart solutions to bridge the regulatory gap and realize FDA approval for innovative products. |
|
|
|
What was once science fiction has moved up to second-line therapy. Dr. Robert Negrin navigates the trajectory of CAR T-Cell Therapy from early HIV therapy to second-line treatment for diffuse large B-cell lymphoma. |
|
|
|
Few & Far Between podcast hosts Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Mass. General Hospital. |
|
|
|
APAC Biopharma: Bridge The Gap To The U.S. FDA | Our regulatory and partner/outsource services are invaluable for biopharma innovators navigating the U.S. FDA regulatory process and developing customized strategies and support for global expansion. See why we're a trusted partner for companies seeking regulatory success. | • Request Information | | |
|
|
|
